Viatris Inc. · NASDAQ:VTRS
Viatris — Q3 2025 Earnings Presentation
21 slides from Viatris's earnings presentation, Nov 6, 2025
Slide 1: GAAP / Non-GAAP Reconciliations
GAAP / Non-GAAP Reconciliations November 6, 2025 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of
Slide 2: Non-GAAP Financial Measures and Other Information
Non-GAAP Financial Measures and Other Information Key References New product sales, new product launches or new product revenues: Refers to revenue from new products launched in 2025 and the carryover impact of new products, including business development, launched within the last 12 months. Operati
Slide 3: Full Year 2025 Financial Guidance Items as of November 6, 2025
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except Adjusted EPS) Full Year 2025 Financial Guidance Items as of November 6, 2025 (1) GAAP Non-GAAP Total Revenues $13,900 - $14,300 N/A Adjusted EBITDA N/A $4,000 - $4,200 Net Cash provided by $
Slide 4: Reconciliation of Estimated 2025 Operating Cash Flow to Free Cash Flow (Nov 6)
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Reconciliation of Estimated 2025 U.S. GAAP Net Cash Provided by Operating Activities to Free Cash Flow as of November 6, 2025 (1) Estimated U.S. GAAP Net Cash provided by Operating Activities $2,20
Slide 5: Full Year 2025 Financial Guidance Items as of August 7, 2025
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except Adjusted EPS) Full Year 2025 Financial Guidance Items as of August 7, 2025 (1) GAAP Non-GAAP Total Revenues $13,500 - $14,000 N/A Adjusted EBITDA N/A $3,890 - $4,190 Net Cash provided by $2,
Slide 6: Reconciliation of Estimated 2025 Operating Cash Flow to Free Cash Flow (Aug 7)
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Reconciliation of Estimated 2025 U.S. GAAP Net Cash Provided by Operating Activities to Free Cash Flow as of August 7, 2025 (1) Estimated U.S. GAAP Net Cash provided by Operating Activities $2,200
Slide 7: U.S. GAAP Net (Loss) Earnings to Adjusted Net Earnings and Adjusted EPS
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except per share amounts) U.S. GAAP Net (Loss) Earnings to Adjusted Net Earnings and U.S. GAAP Diluted (Loss) Earnings Per Share to Adjusted EPS Three Months Ended Nine Months Ended September 30, S
Slide 8: U.S. GAAP Net (Loss) Earnings to EBITDA and Adjusted EBITDA
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) U.S. GAAP Net (Loss) Earnings to EBITDA and Adjusted EBITDA Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP net (loss) earnings.......................
Slide 9: Summary of Total Revenues by Segment – Q3 2025
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except %s) Summary of Total Revenues by Segment – Q3 2025 Three Months Ended September 30, Divestiture- 2025 Constant Constant Closed 2024 Adjusted Adjusted 2025 Currency Currency Currency % Divest
Slide 10: Summary of Total Revenues by Segment – Q3 2025 YTD
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except %s) Summary of Total Revenues by Segment – Q3 2025 YTD Nine Months Ended September 30, Divestiture- 2025 Constant Constant Closed 2024 Adjusted Adjusted 2025 Currency Currency Currency % Div
Slide 11: Key Product Net Sales, on a Consolidated Basis
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Key Product Net Sales, on a Consolidated Basis Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Select Key Global Products Lipitor ® $ 396.1 $ 375.6 $ 1,172.0 $
Slide 12: Cost of Sales
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except %s) Cost of Sales Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP cost of sales................................................................
Slide 13: SG&A
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except %s) SG&A Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP SG&A (a)..............................................................................
Slide 14: R&D
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except %s) R&D Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP R&D....................................................................................
Slide 15: Total Operating Expenses
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Total Operating Expenses Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP total operating expenses........................................ $ 1,192.7 $
Slide 16: Interest Expense
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Interest Expense Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP interest expense.................................................................. $
Slide 17: Other Expense (Income), Net
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Other Expense (Income), Net Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP other expense (income), net...............................................
Slide 18: (Loss) Earnings Before Income Taxes and Income Tax Provision (Benefit)
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except %s) (Loss) Earnings Before Income Taxes and Income Tax Provision (Benefit) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP (loss) earnings befo
Slide 19: Free Cash Flow and Free Cash Flow Excluding Transaction-related Costs
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Free Cash Flow and Free Cash Flow Excluding Transaction-related Costs Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 U.S. GAAP net cash provided by operating a
Slide 20: Gross Leverage – Debt to Adjusted EBITDA
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions, except ratio) Gross Leverage – Debt to Adjusted EBITDA Gross Leverage Ratio is the ratio of Viatris’ total debt at notional amounts at September 30, 2025 to the sum of Viatris’ adjusted EBITDA for
Slide 21: Net Loss to EBITDA and Adjusted EBITDA – Last Twelve Months
Viatris Inc. and Subsidiaries | Reconciliation of Non-GAAP Financial Measures (Unaudited; in millions) Net Loss to EBITDA and Adjusted EBITDA – Last Twelve Months Three Months Ended December 31, 2024 March 31, 2025 June 30, 2025 September 30, 2025 U.S. GAAP net loss..................................